keyboard_arrow_up

Global Antisense and RNAi Therapeutics Market to Grow at 26.79% CAGR by 2018

Global Antisense and RNAi Therapeutics Market 2015-2019 is the latest addition to Sandlerresearch.org industry research reports collection.

Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules. Antisense technology involves the synthesis of a strand of nucleic acid that would bind to an mRNA or to a splicing site on pre-mRNA and inactivates it effectively. RNAi and antisense are two predominant technologies used by pharmaceutical companies, research institutes, and others for various applications such as research, diagnostics, and therapeutics. RNAi therapeutics have a large scope in the treatment of diseases such as cancer and neurodegenerative disorders. There are two types of RNA molecules used in the RNAi technology: miRNA and siRNA.

Analysts forecast the Global Antisense and RNAi Therapeutics market to grow at a CAGR of 26.79 percent over the period 2014-2019.

Single User License of the report is Available at US $2500

The report recognizes the following companies as the key players in the Global Antisense and RNAi Therapeutics Market: Alnylam Pharmaceuticals, Isis Pharmaceuticals, Sanofi SA and Tekmira Pharmaceuticals.

Other Prominent Vendors in the market are: Acuitas Therapeutics, Allergan, Antisense Therapeutics, Ascletis, AstraZeneca, Atlantic Pharmaceuticals, Benitec Biopharma, Biogen Idec, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Dicerna Pharmaceuticals, Enzon Pharmaceuticals, F. Hoffmann-La Roche, GlaxoSmithKline, Gradalis, iCo Therapeutics, Kyowa Hakko Kirin, Marina Biotech, Novartis, OncoGenex Pharmaceuticals, OPKO Health, Pfizer , Quark Pharmaceuticals, Regulus Therapeutics, Silence Therapeutics, Spectrum Pharmaceuticals, Sylentis, Takeda Pharmaceutical, Teva Pharmaceutical, The Medicines Company and TransDerm

One of the main trends upcoming in this market is the increased strategic collaborations and licensing activities. Many big pharmaceutical and biotechnology companies are collaborating with other companies to develop and commercialize antisense and RNAi drugs in the market.

This report covers the present scenario and the growth prospects of the Global Antisense and RNAi Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of antisense and RNAi therapeutics used for the treatment of various serious chronic diseases including:

  • Infectious diseases
  • Cardiovascular diseases
  • Kidney diseases
  • Cancer
  • Metabolic disorders
  • Others

The report also covers the two main technologies, i.e., Antisense and RNAi technology, which are used by vendors to develop antisense and RNAi therapeutics.

Order a copy of this report at (Prices start at US $2500 for a single user PDF) http://www.sandlerresearch.org/purchase?rname=27367 .

Global Antisense and RNAi Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Antisense and RNAi Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, one of the major drivers in this market is the advances in technology. Demand for gene silencing by antisense and RNAi is gaining popularity because of its high efficiency. Advances in technology in antisense and RNAi technology help to design and develop antisense and RNAi therapeutics that can suppress the expression of the targeted genes with high specificity.

Further, the report states that one of the major challenges in this market is the toxicity of antisense and RNAi-based drugs. Therapeutic antisense oligonucleotides and RNAi drugs have adverse side effects on the body especially on the liver.

Table of Contents
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Market Segmentation by Technology
08. Market Segmentation by Therapeutics Area
09. Geographical Segmentation
10. Buying Criteria
11. Pipeline Snapshot
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
19. Key Vendor Analysis
20. Other Reports in this Series

List of Exhibits:

Exhibit 1: Market Research Methodology
Exhibit 2: Global Antisense and RNAi Therapeutics Market 2014-2019 (US$ million)
Exhibit 3: Global Antisense and RNAi Therapeutics Market Segmentation by Technology
Exhibit 4: Global Antisense and RNAi Therapeutics Market Segmentation by Technology 2014
Exhibit 5: Global Antisense and RNAi Therapeutics Market by Therapeutics Area
Exhibit 6: Global Antisense and RNAi Therapeutics Market by Geographical Segmentation 2014
Exhibit 7: Antisense and RNAi Therapeutics Market in Americas 2014-2019 (US$ million)
Exhibit 8: Antisense and RNAi Therapeutics Market in EMEA Region 2014-2019 (US$ million)
Exhibit 9: Antisense and RNAi Therapeutics Market in APAC Region 2014-2019 (US$ million)
Exhibit 10: Global Antisense and RNAi Therapeutics Market by Geographical Segmentation 2014-2019 (US$ million)
View all 18 Exhibits

Have any Query on the Report get your Queries Resolved at http://www.sandlerresearch.org/inquire-before-buying?rname=27367 .

About US:

Sandlerresearch.org (http://www.sandlerresearch.org) is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.